Can fluoxetine (Prozac) cause hypoglycemia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 8, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Fluoxetine Can Cause Hypoglycemia

Yes, fluoxetine (Prozac) can cause hypoglycemia, particularly in patients with diabetes or other conditions affecting glucose metabolism. The FDA drug label explicitly states that in patients with diabetes, fluoxetine may alter glycemic control, and hypoglycemia has occurred during therapy with fluoxetine 1.

Evidence of Fluoxetine-Induced Hypoglycemia

  • The FDA drug label for fluoxetine clearly indicates that hypoglycemia can occur during therapy with fluoxetine, and hyperglycemia has been reported following discontinuation of the drug 1.

  • Case reports have documented fluoxetine-induced hypoglycemia in patients with type 1 diabetes, showing significant reductions in insulin requirements during fluoxetine treatment 2.

  • Fluoxetine has also been reported to cause hypoglycemia in patients with congenital hyperinsulinism, suggesting its effects on blood glucose regulation extend beyond patients with diabetes 3.

Mechanism of Action

  • Research studies demonstrate that fluoxetine can amplify autonomic nervous system (ANS) and metabolic counterregulatory responses during hypoglycemia 4.

  • In patients with type 1 diabetes, 6-week administration of fluoxetine has been shown to increase epinephrine, norepinephrine, and muscle sympathetic nerve activity responses to hypoglycemia 5.

  • These alterations in counterregulatory mechanisms suggest fluoxetine affects glucose homeostasis through serotonergic pathways that influence sympathetic nervous system activity 4.

Risk Factors and Monitoring

  • Patients with diabetes are at particular risk, as they may require adjustments to insulin and/or oral hypoglycemic medication dosages when starting or discontinuing fluoxetine 1.

  • Similar hypoglycemic effects have been observed with other selective serotonin reuptake inhibitors (SSRIs), such as sertraline, suggesting this may be a class effect 6.

  • Clinicians should consider an individual's risk for hypoglycemia when selecting diabetes medications and glycemic goals 7.

Clinical Implications

  • For patients with diabetes who are prescribed fluoxetine, healthcare providers should:

    • Monitor blood glucose levels more frequently after initiating fluoxetine therapy 7, 1.
    • Be prepared to adjust diabetes medication dosages to prevent hypoglycemic episodes 1.
    • Educate patients about recognizing and treating symptoms of hypoglycemia 7.
  • Patients should be informed that symptoms of hypoglycemia include shakiness, irritability, confusion, tachycardia, sweating, and hunger 7.

Management of Hypoglycemia

  • If hypoglycemia occurs (glucose <70 mg/dL or <3.9 mmol/L), treatment with fast-acting carbohydrates containing glucose is recommended 7.

  • For severe hypoglycemia (characterized by altered mental and/or physical status requiring assistance), glucagon administration may be necessary 7.

  • In cases of recurrent hypoglycemia associated with fluoxetine, discontinuation of the medication should be considered, as symptoms typically resolve within days to weeks after stopping the drug 3, 2.

Conclusion

When prescribing fluoxetine, clinicians should be aware of its potential to cause hypoglycemia, especially in patients with diabetes or other conditions affecting glucose metabolism. Careful monitoring of blood glucose levels and appropriate adjustments to diabetes medications may be necessary to prevent hypoglycemic episodes in at-risk patients.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.